Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia | Zendy

N. Môri | Zendy; Mitsuya Katayama | Zendy; Shigenari Nukaga | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia

Author(s) -

N. Môri,

Mitsuya Katayama,

Shigenari Nukaga

Publication year - 2020

Publication title -

journal of microbiology immunology and infection

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.223

H-Index - 57

eISSN - 1995-9133

pISSN - 1684-1182

DOI - 10.1016/j.jmii.2020.09.003

Subject(s) - azithromycin , hydroxychloroquine , ciclesonide , medicine , covid-19 , pneumonia , antibiotics , microbiology and biotechnology , infectious disease (medical specialty) , disease , asthma , inhaled corticosteroids , biology

No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research